A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
← catalyst calendarNCT07090499 · readout in 689 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
310estimated
Sites
30
Countries
Canada, Puerto Rico, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-20 | actual | When the study began enrolling |
| Primary completion | 2028-07-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-08 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced/Metastatic Solid Tumors
- Bladder Cancer
- Urothelial Carcinoma
- Advanced Non-Small Cell Lung Cancer
- Carcinoma, Non Small Cell Lung
- Carcinoma, Squamous Cell of Head and Neck
- Head and Neck Cancer
- Esophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Esophageal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
Intervention
- Drug: PF-08046876
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation
measured Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy
measured Baseline to end of DLT evaluation period
Part 1: Recommended Monotherapy Dose for Expansion
measured Baseline to 30 days post last study drug administration
Part 2: Recommended Phase 2 Dose
measured Baseline to 30 days post last study drug administration
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed